Dosing and Administration
Oral Dosing
Dosing options to accommodate your patients1
Patients previously treated with ≥2 TKIs:
There is also an option to take SCEMBLIX 40 mg tablets twice a day (AM + PM)
Recommended dosage for patients who have the T315I mutation is 200 mg bid AM + PM
Patients should:
Avoid food consumption for at least 2 hours before and 1 hour after taking SCEMBLIX1
Swallow SCEMBLIX whole—do not break, crush, or chew them1
SCEMBLIX is available as film-coated tablets: 20 mg (6.2 mm diameter) and 40 mg (8.2 mm diameter)1
Based on pharmacokinetic parameters studied in an exposure-response analysis, the predicted efficacy and safety profile of SCEMBLIX at the 80 mg once-daily dose is similar to that at the 40 mg bid dose.2
Dosage Reductions
For the management of adverse reactions, reduce the SCEMBLIX dose as described in the table below.
Dosage Adjustments for Adverse Reactions
ANC, absolute neutrophil count; PLT, platelets; ULN, upper limit of normal.
aBased on Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Dosing Modifications Guide
